Oligonucleotide Building Blocks
Advanced monomers, modified nucleosides, and synthesis reagents for PMO, ASO, siRNA, and RNA therapeutics programs.
Innovation Drug Discovery Partner
Advanced drug intermediates, building blocks, and custom synthesis solutions for complex medicinal chemistry programs.
Product Platforms
Each platform supports catalog supply, custom analog development, and project-based scale-up.
Advanced monomers, modified nucleosides, and synthesis reagents for PMO, ASO, siRNA, and RNA therapeutics programs.
Ionizable lipids, PEG lipids, phospholipids, and cholesterol derivatives for nucleic acid delivery research.
Degrader-focused linkers, E3 ligand derivatives, and complex intermediates for targeted protein degradation discovery.
Protected amino acids, unnatural amino acids, and Fmoc derivatives supporting peptide drug discovery and optimization.
Beyond Commercial Chemicals
The website's core conversion path is built around research problems: target, current bottleneck, route risk, timeline, and confidential project review.
Customer research challenge
Technical solution
Custom development
Product and building block supply
Scale-up production
Long-term partnership
From milligram discovery samples to gram and kilogram intermediates for hard-to-source compounds.
Practical synthetic planning for discovery teams that need speed, selectivity, and material access.
Development of high-value intermediates that connect medicinal chemistry ideas to scalable supply.
Optimization, impurity control, and scale-up support for long-term project supply.
From Lab to Supply
Chemistry, analytical, and biology support are presented as one connected development path from feasibility to repeat supply.
Organic synthesis / Medicinal chemistry / Chemical modification / Heterocycle chemistry
LC-MS / HPLC / NMR / Purity analysis / Impurity profiling
Molecular pharmacology / Cellular assays / Discovery collaboration
Confidential Project Review
Submit the research objective, target compound, current challenge, timeline, budget range, and NDA preference for technical review.